747 Phase 1 trial of LYL845, an autologous tumor-infiltrating lymphocyte (TIL) therapy enhanced with epigenetic reprogramming, for the treatment of advanced solid tumors

التفاصيل البيبلوغرافية
العنوان:	747 Phase 1 trial of LYL845, an autologous tumor-infiltrating lymphocyte (TIL) therapy enhanced with epigenetic reprogramming, for the treatment of advanced solid tumors
المؤلفون:	Joal D Beane, Yazan Samhouri, Brent A Hanks, John Hyngstrom, Sarah Weiss, Heidi Gillenwater, Yeonhee Kim, J Randolph Hecht, Bishwa J Ganguly, Hajime Hiraragi, Lucy Gong, Navid Nikoo
المصدر:	Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
بيانات النشر:	BMJ Publishing Group, 2023.
سنة النشر:	2023
المجموعة:	LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
نوع الوثيقة:	article
وصف الملف:	electronic resource
اللغة:	English
تدمد:	2051-1426
Relation:	https://doaj.org/toc/2051-1426
DOI:	10.1136/jitc-2023-SITC2023.0747
URL الوصول:	https://doaj.org/article/131c086eb8404ff79d66b0ec86a836ac
رقم الأكسشن:	edsdoj.131c086eb8404ff79d66b0ec86a836ac
قاعدة البيانات:	Directory of Open Access Journals

الوصف
تدمد:	20511426
DOI:	10.1136/jitc-2023-SITC2023.0747